About Hema.to
Hema.to is a company based in Munchen (Germany) founded in 2019.. Hema.to has raised $7.7 million across 2 funding rounds from investors including LUMO Labs, Bayern Kapital and Elaia. Hema.to offers products and services including hema.to BASE and hema.to B-NHL. Hema.to operates in a competitive market with competitors including PathAI, Deepcell, Aignostics, Pictor Labs and Neko Health, among others.
- Headquarter Munchen, Germany
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hema.To Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.7 M (USD)
in 2 rounds
-
Latest Funding Round
$3.78 M (USD), Seed
Feb 27, 2025
-
Investors
LUMO Labs
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hema.to
Hema.to offers a comprehensive portfolio of products and services, including hema.to BASE and hema.to B-NHL. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Automates single cell classification in cytometry for clinical diagnostics
Offers AI-based recommendations for B-NHL blood cancer diagnosis
Unlock access to complete
Funding Insights of Hema.to
Hema.to has successfully raised a total of $7.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $3.78 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $3.8M
-
First Round
First Round
(26 Jun 2023)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Seed - Hema.to | Valuation | LUMO Labs | |
| Jun, 2023 | Amount | Seed - Hema.to | Valuation | Elaia , Heal Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hema.to
Hema.to has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include LUMO Labs, Bayern Kapital and Elaia. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Opportunities are created for impact-driven ventures in emerging technologies.
|
Founded Year | Domain | Location | |
|
High-tech industries are targeted for investments by Bayern Kapital.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on early-stage investments
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hema.to
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hema.to
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hema.To Comparisons
Competitors of Hema.to
Hema.to operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, Deepcell, Aignostics, Pictor Labs and Neko Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| domain | founded_year | HQ Location |
AI-powered single cell classification and isolation technology for clinical research
|
|
| domain | founded_year | HQ Location |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| domain | founded_year | HQ Location |
AI-based tools for pathological image analysis are provided to labs.
|
|
| domain | founded_year | HQ Location |
Platform offering solutions for preventive health scans
|
|
| domain | founded_year | HQ Location |
Imaging systems and AI software for microscopes are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hema.To
Frequently Asked Questions about Hema.to
When was Hema.to founded?
Hema.to was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Where is Hema.to located?
Hema.to is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Is Hema.to a funded company?
Hema.to is a funded company, having raised a total of $7.7M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3.92M, raised on Jun 26, 2023.
What does Hema.to do?
Hema.to was founded in 2019 and is headquartered in Munich, Germany. Operations focus on the health technology sector, where SaaS platforms integrated with artificial intelligence are utilized for leukemia diagnostics. Services include software tools that assist in analyzing blood samples and identifying leukemia indicators. The company serves medical professionals through cloud-based solutions, emphasizing accuracy in diagnostic processes across European markets.
Who are the top competitors of Hema.to?
Hema.to's top competitors include Aignostics, Pictor Labs and PathAI.
What products or services does Hema.to offer?
Hema.to offers hema.to BASE and hema.to B-NHL.
Who are Hema.to's investors?
Hema.to has 5 investors. Key investors include LUMO Labs, Bayern Kapital, Elaia, Heal Capital, and High-Tech Gründerfonds.